Taiwan´s Kaohsiung Medical University Selects Collexis to Develop the Institution´s Advanced Expert Profiling System

Collexis Holdings, Inc. (OTCBB: CLXS), a leading developer of high
definition search and knowledge discovery software, announced today
that Kaohsiung Medical University (KMU) has selected the company to
develop an Advanced Expert Profiling System that will allow its
students, faculty and researchers to connect via a Web interface and
help maximize productivity and networking abilities for its combined
student, faculty and staff population of more than 15,000.

"Our goal is to provide KMU - a leading medical university in Asia
- with a progressive expert profiling system that is specifically
tailored to meet their current and future needs," said Bill Kirkland,
CEO of Collexis Holdings, Inc. "We´re confident this endeavor will
serve as a mutually beneficial relationship, helping open doors for
Collexis and KMU to facilitate Chinese language-based healthcare and
life sciences activities and explore opportunities for future
collaboration within specific fields of biomedical research. What´s
more, our work with KMU will help expand our marketing opportunities
throughout the Asian market."

KMU selected Collexis for its ability to enhance research and
teaching capabilities, identify areas of productive partnerships and
improve such partnerships both on and off the campus. Other benefits
include the facilitation of further recruitment and team building,
achieving the ultimate goals of improving the overall competitiveness
of the University and helping attain professional excellence.

Dr. Por Lai, managing director for Dephoron Co., Ltd. and an
exclusive sales agent for Collexis in the Asia Pacific region, played
an instrumental role in helping bring KMU together with Collexis. An
outstanding alumnus of KMU, Lai is an experienced life sciences
professional who previously served as a manager at Sequemat, Amgen and
Centocor from 1981 to 1990. He also co-founded the Kirin
Pharmaceuticals Co., Ltd. with Kirin Brewery of Japan and developed
its biopharmaceutical markets in China, Hong Kong and Taiwan.

"We´re excited to work closely with the Collexis team as they
develop an advanced expert profiling system for our university," said
Hsin-Su Yu, M.D., Ph.D, president of Kaohsiung Medical University. "By
helping improve our opportunities for enhanced research capabilities
and collaboration, Collexis´ innovative technology will also help
better position KMU as a significant leader in professional education
and services. Working together with Collexis´ Knowledge Guide System,
we will be able to make more important research contributions to
environmental medicine as well as other health-related sciences, and
seek more international counterpart cooperation," continued Yu.

KMU joins other prestigious institutions that are also using
Collexis´ Advanced Expert Profiling System, including Johns Hopkins
University, the Mayo Clinic, the National Institutes of Health and the
Dana-Farber/Harvard Cancer Center.

About Kaohsiung Medical University

KMU was the first private institution of its kind in Taiwan and
was founded in 1954 by former Kaohsiung Mayor Frank C. Chen, along
with the first college president, Professor Tu. They established a
school with the philosophy of "Joyfully embracing, learning and
putting research first, as well as resolutely striving for progress,
encouraging study and benefitting the world." According to Web of
Science & Essential Scientific Indicators, KMU ranked 75th in the
world in Pharmacology and Toxicology and 387th in the world in
clinical medicine during 1997-2007. Today, KMU has transformed into a
major medical center home to a 2,000-bed medical center, six colleges,
thousands of students and almost 500 researchers. With 25 graduate
schools, seven of which offer Ph.D. programs, KMU focuses not only on
medical treatment and the management of national health, but is also
working toward becoming the leading South Taiwan Medical facility.

About Collexis Holdings, Inc.

Collexis Holdings, Inc., a leading developer of high definition
search and knowledge discovery software since 1999, headquartered in
Columbia, South Carolina (USA) with major operations in Cincinnati,
Ohio, Geldermalsen, the Netherlands and Cologne, Germany. Collexis now
offers the world´s first pre-populated professional social network for
life science researchers, www.biomedexperts.com. Collexis´ proprietary
technology builds conceptual profiles of text, called Fingerprints,
from documents, Websites, emails and other digitized content and
matches them with a comprehensive list of pre-defined "fingerprinted"
concepts to make research results more relevant and efficient. This
matching of concepts eliminates the ambiguity and lack of priority
associated with word searches. The results are often described as
"finding needles in many haystacks." Through this novel approach,
Collexis can build unique applications to search, index and aggregate
information as well as prioritize, trend and predict data based on
sources in multiple industries without the limitations of language or
dialect. Collexis´ current clients in the public, private and academic
sectors include the Mayo Clinic; Johns Hopkins University; the
University of California, San Francisco; the University of South
Carolina; Erasmus University Library; Bristol-Myers Squibb; Lockheed
Martin; the World Health Organization; Wellcome Trust; the National
Institutes of Health; and the U.S. Department of Defense. Shares of
Collexis common stock are traded under the symbol CLXS on the OTC
Bulletin Board (OTC BB). For more information, visit www.collexis.com.

Forward-Looking Statements

Some of the statements made in this press release may constitute
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. These forward-looking
statements are based on management´s current expectations and include
known and unknown risks, uncertainties and other factors, many of
which the company is unable to predict or control, that may cause the
company´s actual results or performance to differ materially from any
future results or performance expressed or implied by such
forward-looking statements. These statements involve risks and
uncertainties, including risks and uncertainties associated with the
announcement to develop an expert profiling system for KMU. These
risks and uncertainties are in addition to other factors detailed from
time to time in the company´s filings with the SEC, including the
section entitled "Risk Factors" in its transition report on Form
10-KSB for the period ended June 30, 2007, as amended. The company
cautions investors that any forward-looking statements made by the
company are not necessarily indicative of future performance. The
company is not responsible for updating the information contained in
this press release beyond the published date, or for changes made to
this document by wire services or Internet services.